Who qualifies for Ozempic?
Ozempic (semaglutide) is FDA-approved only for adults with type 2 diabetes to control blood sugar levels alongside diet and exercise, or to reduce cardiovascular risk in those with established heart disease and type 2 diabetes.[1] It is not approved for weight loss alone, though doctors sometimes prescribe it off-label for obesity under specific conditions.
What conditions must you have?
- Primary approval: Type 2 diabetes (not type 1 or diabetic ketoacidosis). Patients typically need poor glycemic control despite metformin or other oral meds.[1][2]
- Secondary approval: Type 2 diabetes plus known cardiovascular disease, to lower risks of heart attack, stroke, or death.[1]
- Off-label use for weight loss: Requires BMI ≥30 (obese) or ≥27 with weight-related issues like hypertension or high cholesterol. This follows Wegovy guidelines (same drug, higher dose approved for obesity), but Ozempic shortages have led to its off-label use.[3]
What steps to become a patient?
- Get diagnosed by a doctor (endocrinologist, primary care, or obesity specialist) via blood tests (A1C ≥6.5% confirms type 2 diabetes) and medical history review.
- Discuss lifestyle changes—Ozempic requires diet/exercise commitment; it's not a standalone fix.
- Receive a prescription: Starts at 0.25 mg weekly injection, titrated up. Insurance often covers for approved uses if criteria met (e.g., failed metformin trial).[2]
- Monitor for eligibility exclusions (see below).
Insurance and cost requirements
Most U.S. insurers cover Ozempic for type 2 diabetes if prior authorizations show medical necessity (e.g., A1C targets unmet). Copays range $25–$100/month with coverage; list price is ~$1,000/month without.[4] Medicare Part D covers it for diabetes but not weight loss. Off-label use may require appeals or out-of-pocket payment.
Who cannot use Ozempic?
Excluded patients include:
- Personal/family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
- History of severe allergic reaction to semaglutide.
- Pregnancy, breastfeeding, or planning pregnancy (stop 2 months prior).
- Severe gastrointestinal disease or pancreatitis history.
- Age under 18 (not approved).[1][2]
Doctors assess risks like thyroid tumors (from animal studies), pancreatitis, or gallbladder issues before prescribing.
How does it compare to alternatives like Wegovy or Mounjaro?
Ozempic focuses on diabetes; Wegovy (semaglutide 2.4 mg) is approved for chronic weight management ≥12 weeks diet/exercise failed. Mounjaro (tirzepatide) treats diabetes and obesity with dual hormone action, often showing more weight loss.[3] Switching depends on insurance and goals.
[1]: FDA Ozempic Label
[2]: Novo Nordisk Prescribing Info
[3]: FDA Wegovy Label
[4]: GoodRx Ozempic Pricing